Search
Search Results
-
Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer
BackgroundPatients from non-small cell lung cancer (NSCLC) controlled clinical trials do not always reflect real-world heterogeneous patient...
-
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
BackgroundThis study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting in Vietnam.
...
-
Differences in small-world networks between methamphetamine and heroin use disorder patients and their relationship with psychiatric symptoms
Both methamphetamine use disorder (MAUD) and heroin use disorder (HUD) implicated in substance-induced psychosis, but the psychiatirc symptoms...
-
Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study
BackgroundPaclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to...
-
Disrupted small-world white matter networks in patients with major depression and recent suicide plans or attempts
Suicide is a major concern for health, and depression is an established proximal risk factor for suicide. This study aimed to investigate white...
-
Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey
BackgroundThe landscape of non-small cell lung cancer (NSCLC) therapy is rapidly changing. This analysis aimed to understand patient characteristics,...
-
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis
BackgroundImmunotherapy in combination with platinum-etoposide (EP) chemotherapy has been approved as a first-line treatment for extensive-stage...
-
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
PurposeFor the first-line treatment of KRAS mutant non-small cell lung cancer (NSCLC) patients, immunotherapy or platinum-based chemotherapy are the...
-
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
BackgroundRecent reports suggested combining ramucirumab with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to overcome...
-
Long-term results of postoperative unsuspected small cell lung cancer on real-world data
BackgroundIn traditional opinion, solid pulmonary nodule suspected lung cancer should be confirmed by pathology before the operation to exclude small...
-
Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world
The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial...
-
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis
BackgroundAs part of the multi-country I-O Optimise research initiative, this population-based study evaluated real-world treatment patterns and...
-
Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study
BackgroundGenitourinary small cell carcinoma is rare, and has a poor prognosis. However, effective treatment options for this disease are limited. We...
-
Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
BackgroundThe CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival rate in patients with extensive stage...
-
Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis
BackgroundIn view of the limited data on radiotherapy (RT) combined with immunotherapy in patients with extensive-stage small cell lung cancer...
-
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
BackgroundBoth first and second-generation EGFR-TKIs are recommended in advanced NSCLC with common EGFR mutations. However, there are few data on the...
-
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
BackgroundKRAS mutations occur frequently in advanced non-small cell lung cancer (aNSCLC); the G12C mutation is the most prevalent. Alterations in STK11...
-
-
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
BackgroundNon-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis...
-
Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1–4 brain metastases
PurposeStereotactic radiosurgery (SRS) has become a standard approach for the treatment of patients with few metastatic brain lesions. However, the...
